

# STATE OF COLORADO

---



Colorado Department  
of Public Health  
and Environment

**Request for Information #52  
Concerning Department AIDS Drug Assistance Program  
(Ryan White Act) Activities**

Submitted to the Colorado Legislature  
(Joint Budget Committee and House Leadership)  
by the Budgeting, Planning and Analysis Unit and the Division of Disease Control and  
Environmental Epidemiology  
Colorado Department of Public Health and Environment  
October 20, 2011

## DOCUMENT INFORMATION

Title: Request for Information #52

Principal Author: Bob Bongiovanni, Program Manager

Contributing Authors: Todd Grove, Insurance Coordinator

Technical Assistance and Preparation: Kristopher Nicklaus, Ramsell Corporation (the contracted pharmacy benefit manager for the program)

Subject: A report detailing the Department's activities relating to the AIDS Drug Assistance Program (Ryan White Act) for the twelve month period (July 1, 2010 - June 30, 2011).

Date: October 20, 2011

Number of pages: 1x pages including cover page

FTE hours used in developing report (and estimated cost): 35 hours used at an average cost of \$2,012

For additional information or copies:

Kim Fear, Budget Director  
Budgeting, Planning and Analysis Unit  
Colorado Department of Public Health and Environment  
4300 Cherry Creek Drive South  
Denver, Colorado 80246-1530  
(303) 692-2044

# ADAP Narrative Report

The AIDS Drug Assistance Program (ADAP) provides formulary medications on an outpatient basis, free of charge to Colorado residents who have HIV disease and who meet the financial eligibility criteria. The program is funded with federal and state dollars. Federal dollars are allocated from the Health Resources and Services Administration (HRSA) through The Ryan White HIV/AIDS Treatment Extension Act of 2009. State dollars are received from allocations from the General Fund and Tobacco Settlement fund.

The ADAP formulary currently includes all of the FDA approved antiretroviral medications and most of the medications to treat opportunistic infections associated with HIV disease. These life saving medications reduce the occurrence of expensive and long-term hospital stays, keep people out of emergency rooms due to complications from opportunistic infections associated with the disease, allow people to keep working and be productive members of our society, and improve the quality and length of life for those affected by the epidemic.

Colorado supports three mechanisms in support of improved access to formulary medications. epidemic.

## 1) Medicare Wrap Around

Some People Living With HIV or AIDS (PLWHA) are so severely disabled by their condition that they qualify for Medicare, including Medicare Part D prescription drug plans. For these individuals, Colorado ADAP offers "wrap around" assistance paying for premiums, co-payments, and other out-of-pocket costs. Without assistance, these clients would be economically unable to meet the costs of the associated copayments and premiums. They would also be unable to afford to pay all of their medication costs during the "coverage gap," resulting in either a return to the ADAP direct medication assistance program or a lapse in medication adherence. It has proven to be cost-saving to ADAP to subsidize their premiums, copayments, and other out-of-pocket costs. The ADAP assistance "wraps around" the Medicare Part D coverage, leaving the majority of the costs being born by Medicare.

## 2) HIV Insurance Assistance

A second group of PLWHA is able to access insurance through their employer, or through COBRA (Consolidated Budget Reconciliation Act) – related insurance extension after they have left a former employer. For these individuals, Colorado ADAP offers varying levels of assistance in maintaining this insurance, be it through premium, co-insurance, deductibles, or co-payments. Without assistance, these clients would be economically unable to meet the costs of the associated copayments and premiums. It has proven to be cost-saving to ADAP to subsidize their premiums, copayments, and other out-of-pocket costs. The ADAP assistance "wraps around" health insurance coverage, leaving the majority of the costs being born by the insurance company.

## 3) Direct Medication Assistance

Other people living with HIV have no access to Medicare or other insurance coverage; they receive their medications directly, at either an ADAP-affiliated pharmacy or through mail order from Walgreens at Rose Hospital in Denver.

In the 2010/2011 fiscal year, Colorado ADAP made significant upgrades to its data system, which allowed for the collection of detailed claim information on clients receiving assistance with private insurance and Medicare. This allowed ADAP to begin requesting rebates from pharmaceutical manufacturers on claims where any amount of ADAP assistance was provided (such as the cost of a copayment). By June 30, 2011 over \$1 million in such rebates had been received by the program. Consistent with federal law, these rebate funds were utilized to purchase additional HIV medications for eligible enrollees. This has assisted ADAP to meet the needs of an increasing number of eligible enrollees.

**ADAP Report**  
**Monthly Costs July 2010-June 2011**

	<b>Direct Medication Assistance (Note 1)</b>	<b>Assistance Through Medicare Wrap Around (Note 2)</b>	<b>HIV Insurance Assistance (Note 3)</b>
<b>Total Number of Clients Served:</b>	<b>1,811</b>	<b>761</b>	<b>337</b>
<b>Average Monthly Clients Served:</b>	<b>1,230</b>	<b>366</b>	<b>163</b>
<b>Client Demographics:</b>			
Gender			
Female	14.4%	10.1%	27.7%
Male	84.8%	89.7%	72.3%
Transgender	0.8%	0.2%	0.0%
Age			
< 2 years	0.0%	0.0%	0.0%
2-12 years	0.3%	0.0%	2.2%
13-24 years	2.9%	0.3%	0.0%
25-44 years	53.6%	17.5%	53.2%
45-64 years	42.9%	71.1%	42.5%
>65 years	0.3%	11.1%	2.1%
Ethnicity			
Hispanic	31.7%	17.0%	21.3%
Non-Hispanic	68.3%	83.0%	78.7%
Race			
African American (non-Hispanic)	23.9%	17.0%	27.0%
American Indian or Alaska Native	2.3%	1.6%	0.0%
Asian	1.9%	0.2%	2.7%
More than one race	2.3%	1.9%	13.5%
Native Hawaiian or Other Pacific Islander	0.2%	0.0%	0.0%
White (non-Hispanic)	66.0%	76.7%	56.7%
Unknown	3.4%	2.6%	0.0%

## ADAP Report

Total and Average Monthly Costs for ADAP Formulary Medications July 2010-June 2011

Medications	Direct Medication Assistance		Assistance Through Medicare Wrap		HIV Insurance Assistance	
	Total Costs	Ave Monthly Costs	Total Costs	Ave Monthly Costs	Total Costs	Ave Monthly Costs
ACYCLOVIR	\$19,646	\$1,637	\$2,916	\$243	\$1,184	\$99
ALINIA	\$1,006	\$84	\$0	\$0	\$0	\$0
APTIVUS	\$4,563	\$380	\$1,475	\$123	\$0	\$0
ATRIPLA	\$4,172,034	\$347,669	\$139,191	\$11,599	\$116,572	\$9,714
AZITHROMYCIN	\$7,919	\$660	\$1,101	\$92	\$622	\$52
CLARITHROMYCIN	\$95	\$8	\$0	\$0	\$67	\$6
CLINDAMYCIN HCL	\$107	\$9	\$54	\$5	\$0	\$0
COMBIVIR	\$266,943	\$22,245	\$27,408	\$2,284	\$9,368	\$781
COZAAR	\$152	\$13	\$73	\$6	\$0	\$0
CRIXIVAN	\$803	\$67	\$819	\$68	\$0	\$0
DAPSONE	\$10,692	\$891	\$1,529	\$127	\$520	\$43
DARAPRIM	\$2,758	\$230	\$0	\$0	\$36	\$3
DIDANOSINE	\$9,844	\$820	\$1,939	\$162	\$535	\$45
EMTRIVA	\$2,807	\$234	\$2,402	\$200	\$245	\$20
EPIVIR	\$38,951	\$3,246	\$10,524	\$877	\$3,302	\$275
EPZICOM	\$401,876	\$33,490	\$29,177	\$2,431	\$13,381	\$1,115
ETHAMBUTOL HCL	\$4,253	\$354	\$198	\$17	\$116	\$10
FLUCONAZOLE	\$3,554	\$296	\$978	\$81	\$293	\$24
GEODON	\$26,635	\$2,220	\$4,666	\$389	\$1,907	\$159
INTELENCE	\$186,970	\$15,581	\$25,529	\$2,127	\$5,289	\$441
INVIRASE	\$20,249	\$1,687	\$1,814	\$151	\$866	\$72
ISENTRISS	\$1,163,543	\$96,962	\$96,203	\$8,017	\$36,106	\$3,009
ITRACONAZOLE	\$2,676	\$223	\$17	\$1	\$0	\$0
KALETRA	\$402,433	\$33,536	\$36,844	\$3,070	\$16,283	\$1,357
LEXIVA	\$122,193	\$10,183	\$8,494	\$708	\$5,494	\$458
LIPITOR	\$83,983	\$6,999	\$9,718	\$810	\$4,066	\$339
LOSARTAN POTASSIUM	\$10,634	\$886	\$960	\$80	\$98	\$8
MEPRON	\$41,610	\$3,468	\$3,632	\$303	\$229	\$19
MYCOBUTIN	\$2,711	\$226	\$0	\$0	\$175	\$15
NEBUPENT	\$2,146	\$179	\$12	\$1	\$0	\$0
NORVIR	\$162,623	\$13,552	\$49,455	\$4,121	\$34,242	\$2,853
PREZISTA	\$1,252,404	\$104,367	\$47,646	\$3,971	\$12,804	\$1,067
RETROVIR	\$0	\$0	\$0	\$0	\$66	\$5
REYATAZ	\$1,843,577	\$153,631	\$67,314	\$5,609	\$38,166	\$3,180
SELZENTRY	\$40,029	\$3,336	\$2,412	\$201	\$92	\$8
SEROQUEL	\$59,921	\$4,993	\$7,790	\$649	\$1,759	\$147
STAVUDINE	\$9,197	\$766	\$1,040	\$87	\$38	\$3
SULFADIAZINE	\$3,799	\$317	\$0	\$0	\$56	\$5
SULFAMETHOXAZOLE	\$19,348	\$1,612	\$3,118	\$260	\$2,489	\$207
SUSTIVA	\$135,902	\$11,325	\$21,427	\$1,786	\$8,111	\$676
TRICOR	\$20,465	\$1,705	\$3,824	\$319	\$1,017	\$85

## ADAP Report

Total and Average Monthly Costs for ADAP Formulary Medications July 2010-June 2011

Medications	Direct Medication Assistance		Assistance Through Medicare Wrap		HIV Insurance Assistance	
	Total Costs	Ave Monthly Costs	Total Costs	Ave Monthly Costs	Total Costs	Ave Monthly Costs
TRIZIVIR	\$185,330	\$15,444	\$8,989	\$749	\$4,044	\$337
TRUVADA	\$2,651,058	\$220,921	\$137,970	\$11,498	\$74,330	\$6,194
VALACYCLOVIR	\$45,637	\$3,803	\$3,001	\$250	\$961	\$80
VALCYTE	\$23,762	\$1,980	\$97	\$8	\$0	\$0
VALTREX	\$27,174	\$2,264	\$1,358	\$113	\$4,482	\$374
VFEND	\$17,084	\$1,424	\$1,477	\$123	\$0	\$0
VIRACEPT	\$75,985	\$6,332	\$5,810	\$484	\$0	\$0
VIRAMUNE	\$159,967	\$13,331	\$23,228	\$1,936	\$6,422	\$535
VIREAD	\$144,517	\$12,043	\$27,104	\$2,259	\$10,550	\$879
ZIAGEN	\$54,781	\$4,565	\$9,580	\$798	\$4,195	\$350
ZIDOVUDINE	\$1,737	\$145	\$440	\$37	\$597	\$50
ZOVIRAX	\$37	\$3	\$36	\$3	\$0	\$0
ZYPREXA	\$16,671	\$1,389	\$1,489	\$124	\$36	\$3
<b>TOTALS</b>	<b>\$13,964,789</b>	<b>\$1,163,732</b>	<b>\$832,277</b>	<b>\$69,356</b>	<b>\$421,175</b>	<b>\$35,098</b>

## ADAP Colorado Report

July 2010 through June 2011

**SOURCES OF FUNDING:**

FEDERAL*	SGA**	Other***	Rebates****	<b>TOTAL FUNDING</b>
\$ 10,449,038	\$ 1,357,760	\$ 3,578,496	\$ 1,153,054	\$ 16,538,349

**ADMINISTRATIVE COSTS:**

FEDERAL*	SGA**	Other***	Rebates****	<b>TOTAL ADMIN</b>	Percent of Total
\$ 811,223	\$ 356	\$ 31,405	\$ -	\$ 842,984	5.1%

- \* Federal HRSA Part B funding from July 1, 2010 through June 30, 2011 includes overlapping grant years.
- \*\* The State General Assembly funding from July 1, 2010 through June 30, 2011
- \*\*\* Tobacco Settlement Funds (CFE) July 1, 2010 Through June 30, 2011
- \*\*\*\* Rebates received on or before June 30, 2011 arising from claims involving insured or Medicare enrollees and partial payment from ADAP.

**AIDS Drug Assistance Program Formulary**  
**July 2010 - June 2011**

**Average Cost for a Month's Supply of Each Medication**

Medications	Direct Medication Assistance	Assistance Through Medicare Wrap Around	HIV Insurance Assistance
ACYCLOVIR	\$52.97	\$10.61	\$17.50
ALINIA	\$335.37	NA	NA
APTIVUS	\$760.48	\$122.92	NA
ATRIPLA	\$720.06	\$186.33	\$202.73
AZITHROMYCIN	\$14.12	\$12.57	\$15.83
CLARITHROMYCIN	\$19.02	\$0.00	\$20.58
CLINDAMYCIN HCL	\$10.18	\$7.73	NA
COMBIVIR	\$389.80	\$90.34	\$104.46
COZAAR	\$8.82	\$12.13	NA
CRIXIVAN	\$127.98	\$68.25	NA
DAPSONE	\$40.50	\$14.16	\$20.78
DARAPRIM	\$446.72	NA	\$11.85
DIDANOSINE	\$122.20	\$25.06	\$19.02
EMTRIVA	\$175.45	\$42.89	\$30.58
EPIVIR	\$229.00	\$32.82	\$57.52
EPZICOM	\$452.78	\$73.14	\$93.74
ETHAMBUTOL HCL	\$57.12	\$9.02	\$38.69
FLUCONAZOLE	\$13.20	\$10.39	\$15.07
GEODON	\$145.75	\$43.28	\$65.53
INTELENCE	\$703.62	\$73.16	\$71.47
INVIRASE	\$470.90	\$58.51	\$144.35
ISENTRESS	\$579.17	\$98.67	\$98.65
ITRACONAZOLE	\$72.76	\$8.33	NA
KALETRA	\$289.72	\$84.31	\$101.02
LEXIVA	\$484.46	\$61.84	\$106.59
LIPITOR	\$68.67	\$27.42	\$38.48
LOSARTAN POTASSIUM	\$61.57	\$12.02	\$14.75
MEPRON	\$682.13	\$134.50	\$32.72
MYCOBUTIN	\$117.89	\$0.00	\$58.31
NEBUPENT	\$42.08	\$12.13	NA
NORVIR	\$21.81	\$26.50	\$56.72
PREZISTA	\$610.14	\$86.63	\$65.41
RETROVIR	NA	NA	\$65.58
REYATAZ	\$524.31	\$73.34	\$76.69
SELZENTRY	\$925.52	\$79.03	\$30.58
SEROQUEL	\$118.23	\$29.26	\$97.27
STAVUDINE	\$241.74	\$25.46	\$9.58
SULFADIAZINE	\$422.06	NA	\$55.58
SULFAMETHOXAZOLE	\$14.01	\$10.66	\$13.89
SUSTIVA	\$253.44	\$33.93	\$82.76
TRICOR	\$48.66	\$17.93	\$78.25
TRIZIVIR	\$1,202.12	\$71.37	\$282.85
TRUVADA	\$413.26	\$91.01	\$96.78



**AIDS Drug Assistance Program Formulary**  
**July 2010 - June 2011**

**Average Cost for a Month's Supply of Each Medication**

Medications	Direct Medication Assistance	Assistance Through Medicare Wrap Around	HIV Insurance Assistance
VALACYCLOVIR	\$303.69	\$44.50	\$26.70
VALCYTE	\$1,584.14	\$12.13	NA
VALTREX	\$62.86	\$44.06	\$138.04
VFEND	\$776.55	\$738.36	NA
VIRACEPT	\$527.68	\$81.84	NA
VIRAMUNE	\$346.18	\$39.23	\$181.02
VIREAD	\$244.94	\$59.44	\$74.82
ZIAGEN	\$443.87	\$49.25	\$107.95
ZIDOVUDINE	\$41.17	\$9.15	\$55.01
ZOVIRAX	\$18.63	\$12.13	NA
ZYPREXA	\$218.22	\$22.12	\$35.58

NA = Insufficient claim history during the fiscal year to calculate this figure.

**AIDS Drug Assistance Program Formulary**  
**July 1, 2010 through June 30, 2011**

Brand Name	Generic Name	Brief description	Manufacturer
Aptivus	Tipranivir	ANTIRETROVIRAL	Boehringer-Ingelheim
Atripla	Emtricitabine/Tenofovir/Efavirenz	ANTIRETROVIRAL	Gilead Sciences and Bristol-Myers Squibb
Combivir	Zidovudine/Lamivudine	ANTIRETROVIRAL	Viiv Healthcare
Crixivan	Indinavir	ANTIRETROVIRAL	Merck
Edurant	Rilpivirine	ANTIRETROVIRAL	Janssen
Emtriva	Emtricitabine (FTC)	ANTIRETROVIRAL	Gilead Sciences
Epivir	Lamivudine (3TC)	ANTIRETROVIRAL	Viiv Healthcare
Epzicom	Abacavir/Lamivudine	ANTIRETROVIRAL	Viiv Healthcare
Fuzeon	Enfuvirtide (T-20)	ANTIRETROVIRAL	Roche
Intelence	Etravirine	ANTIRETROVIRAL	Janssen
Invirase	Saquinavir Mesylate	ANTIRETROVIRAL	Roche
Isentress	Raltegravir	ANTIRETROVIRAL	Merck
Kaletra	Lopinavir/Ritonavir	ANTIRETROVIRAL	Abbott
Levixa	Fosamprenavir	ANTIRETROVIRAL	Viiv Healthcare
Norvir	Ritonavir	ANTIRETROVIRAL	Abbott
Prezista	Darunavir	ANTIRETROVIRAL	Janssen
Rescriptor	Delaviradine	ANTIRETROVIRAL	Viiv Healthcare
Retrovir	Zidovudine (AZT)	ANTIRETROVIRAL	Viiv Healthcare
Reyataz	Atazanavir	ANTIRETROVIRAL	Bristol-Myers Squibb
Selzentry	Maraviroc	ANTIRETROVIRAL	Viiv Healthcare
Sustiva	Efavirenz	ANTIRETROVIRAL	Bristol-Myers Squibb
Trizivir	Zidovudine/Lamivudine/Abacavir	ANTIRETROVIRAL	Viiv Healthcare
Truvada	Emtricitabine/Tenofovir	ANTIRETROVIRAL	Gilead Sciences
Videx	Didanosine (ddI)	ANTIRETROVIRAL	Bristol-Myers Squibb
Videx EC	Didanosine EC	ANTIRETROVIRAL	Bristol-Myers Squibb
Viracept	Nelfinavir	ANTIRETROVIRAL	Viiv Healthcare
Viramune	Nevirapine	ANTIRETROVIRAL	Boehringer-Ingelheim
Viramune XR	Nevirapine	ANTIRETROVIRAL	Boehringer-Ingelheim
Viread	Tenofovir	ANTIRETROVIRAL	Gilead Sciences
Zerit	Stavudine (d4T)	ANTIRETROVIRAL	Bristol-Myers Squibb
Ziagen	Abacavir	ANTIRETROVIRAL	Viiv Healthcare
Alinia	Nitazoxanide	ANTIPROTOZOAL DRUGS,MISCELLANEOUS	Romark
Biaxin	Clarithromycin	OPPORTINISTIC INFECTION MEDICATIONS	Abbott
Cleocin	Clindamycin	OPPORTINISTIC INFECTION MEDICATIONS	Pharmacia & Upjohn
Cozaar	Losartan	ANTIHYPERTENSIVES	Merck
Cytovene	Gancyclovir	OPPORTINISTIC INFECTION MEDICATIONS	Roche
Dapsone	Dapsone	OPPORTINISTIC INFECTION MEDICATIONS	Jacobus
Daraprim	Pyrimethamine	OPPORTINISTIC INFECTION MEDICATIONS	GlaxoSmithKline
Diflucan	Fluconazole	OPPORTINISTIC INFECTION MEDICATIONS	Pfizer
Foscavir	Foscarnet	OPPORTINISTIC INFECTION MEDICATIONS	AstraZeneca LP
Fungizone	Amphotericin Injection	OPPORTINISTIC INFECTION MEDICATIONS	Geneva/Apothecon
Geodon	Ziprasidone	PSYCHOTROPIC MEDICATIONS	Pfizer
Lipitor	Atorvastatin	ANTIHYPERLIPIDEMIC	Pfizer
Mepron	Atovaquone	ANTIPROTOZOAL DRUGS,MISCELLANEOUS	GlaxoSmithKline
Myambutol	Ethambutol	OPPORTINISTIC INFECTION MEDICATIONS	Dura
Mycobutin	Rifabutin	OPPORTINISTIC INFECTION MEDICATIONS	Pharmacia & Upjohn
Nebupent	Pentamidine, aerosol	OPPORTINISTIC INFECTION MEDICATIONS	APP-Amer Pharm
Septra, Bactrim	Sulfamethoxazole/Trimethoprim	OPPORTINISTIC INFECTION MEDICATIONS	Monarch
Seroquel	Quetiapine	PSYCHOTROPIC MEDICATIONS	AstraZeneca LP
Sporanox	Itraconazole	OPPORTINISTIC INFECTION MEDICATIONS	Janssen
Sulfadiazine	Sulfadiazine	OPPORTINISTIC INFECTION MEDICATIONS	Eon
Tricor	Fenofibrate	LIPOTROPICS	Abbott
Valcyte	Valganciclovir	OPPORTINISTIC INFECTION MEDICATIONS	Roche
Valtrex	Valacyclovir	OPPORTINISTIC INFECTION MEDICATIONS	GlaxoSmithKline
Vfend	Voriconazole	ANTIFUNGAL AGENTS	Pfizer
Zithromax	Azithromycin	OPPORTINISTIC INFECTION MEDICATIONS	Pfizer
Zovirax	Acyclovir	OPPORTINISTIC INFECTION MEDICATIONS	GlaxoSmithKline
Zyprexa	Olanzapine	PSYCHOTROPIC MEDICATIONS	Eli Lilly